In Vivo Delivery of Sirna to Immune Cells by Conjugation to a TLR9 Agonist Enhances Antitumor Immune Responses

Marcin Kortylewski,Piotr Swiderski,Andreas Herrmann,Lin Wang,Claudia Kowolik,Maciej Kujawski,Heehyoung Lee,Anna Scuto,Yong Liu,Chunmei Yang,Jiehui Deng,Harris S Soifer,Andrew Raubitschek,Stephen Forman,John J Rossi,Drew M Pardoll,Richard Jove,Hua Yu

DOI: https://doi.org/10.1038/nbt.1564

IF: 46.9

2009-01-01

Nature Biotechnology

Abstract:Efficient delivery of small interfering (si)RNA to specific cell populations in vivo remains a formidable challenge to its successful therapeutic application. We show that siRNA synthetically linked to a CpG oligonucleotide agonist of toll-like receptor (TLR)9 targets and silences genes in TLR9(+) myeloid cells and B cells, both of which are key components of the tumor microenvironment. When a CpG-conjugated siRNA that targets the immune suppressor gene Stat3 is injected in mice either locally at the tumor site or intravenously, it enters tumor-associated dendritic cells, macrophages and B cells. Silencing of Stat3 leads to activation of tumor-associated immune cells and ultimately to potent antitumor immune responses. Our findings demonstrate the potential of TLR agonist-siRNA conjugates for targeted gene silencing coupled with TLR stimulation and immune activation in the tumor microenvironment.